BRPI0509220A - método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio - Google Patents

método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio

Info

Publication number
BRPI0509220A
BRPI0509220A BRPI0509220-5A BRPI0509220A BRPI0509220A BR PI0509220 A BRPI0509220 A BR PI0509220A BR PI0509220 A BRPI0509220 A BR PI0509220A BR PI0509220 A BRPI0509220 A BR PI0509220A
Authority
BR
Brazil
Prior art keywords
treatment
epithelium
modern
kit
cells
Prior art date
Application number
BRPI0509220-5A
Other languages
English (en)
Inventor
Stephen P Bartels
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0509220(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of BRPI0509220A publication Critical patent/BRPI0509220A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Abstract

"MéTODO, FORMULAçãO OFTáLMICA E KIT PARA PARA O TRATAMENTO DE OLHO RESSECADO MODERADO A GRAVE; MéTODO PARA O TRATAMENTO DE OLHO RESSECADO CRÈNICO; E MéTODOS PARA REDUZIR A VERMELHIDãO E A PRODUçãO DE CITOCINAS INFLAMATóRIAS POR CéLULAS NO EPITéLIO". Descrito em modalidades no presente documento está um método de tratamento de olho ressecado moderado a grave em um paciente necessitando do mesmo, sendo que o método compreende administrar etabonato de loteprednol de forma tópica no paciente em um veículo aceitável do ponto de vista oftálmico.
BRPI0509220-5A 2004-03-25 2005-03-24 método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio BRPI0509220A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55616104P 2004-03-25 2004-03-25
PCT/US2005/009761 WO2005094836A2 (en) 2004-03-25 2005-03-24 Use of loteprednol etabonate for the treatment of dry eye

Publications (1)

Publication Number Publication Date
BRPI0509220A true BRPI0509220A (pt) 2007-09-04

Family

ID=34963566

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509220-5A BRPI0509220A (pt) 2004-03-25 2005-03-24 método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio

Country Status (15)

Country Link
US (1) US20050222110A1 (pt)
EP (2) EP2127655A1 (pt)
JP (1) JP2007530573A (pt)
KR (1) KR20070004750A (pt)
CN (1) CN1964719B (pt)
AT (1) ATE441419T1 (pt)
AU (1) AU2005229006B9 (pt)
BR (1) BRPI0509220A (pt)
CA (1) CA2560824A1 (pt)
DE (1) DE602005016392D1 (pt)
ES (1) ES2330762T3 (pt)
HK (1) HK1102551A1 (pt)
MX (1) MXPA06010849A (pt)
TW (1) TW200602030A (pt)
WO (1) WO2005094836A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
CN101317847B (zh) * 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis
WO2013133980A1 (en) * 2012-03-05 2013-09-12 Bausch & Lomb Incorporated Nitroxy derivatives of soft steroids
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256064B2 (en) 2012-05-03 2018-01-04 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN107915751A (zh) 2013-02-20 2018-04-17 卡拉制药公司 治疗性化合物和其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3062618B1 (en) 2013-11-01 2020-02-05 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN106279324A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
CN106279325A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
CN106892953A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
CN106892952A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN109688818A (zh) 2016-09-08 2019-04-26 卡拉制药公司 治疗化合物的晶型及其用途
US10555947B2 (en) * 2017-05-19 2020-02-11 Ocugen, Inc. Ophthalmic compositions and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075A (en) 1847-04-17 Improvement in cultivators
US104A (en) 1836-12-10 Revolving hokse-rake
US6610675B1 (en) 1980-07-10 2003-08-26 Nicholas S. Bodor Inactive metabolite approach to soft drug design
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
ES2084722T3 (es) 1990-05-29 1996-05-16 Boston Ocular Res Composicion para tratamiento del ojo seco.
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US7073504B2 (en) * 1996-12-18 2006-07-11 Ams Research Corporation Contraceptive system and method of use
US6096052A (en) * 1998-07-08 2000-08-01 Ovion, Inc. Occluding device and method of use
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
DE19947234A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
JP2004531560A (ja) 2001-05-21 2004-10-14 アルコン,インコーポレイテッド ドライアイ障害を処置する方法
PL369960A1 (en) * 2001-10-11 2005-05-02 Alcon, Inc. Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue
EP1476135A1 (en) * 2002-02-22 2004-11-17 Pharmacia Corporation Ophthalmic formulation with gum system
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
EP1572216A1 (en) * 2002-12-20 2005-09-14 Control Delivery Systems, Inc. Steroid compositions for intraocular use
WO2004073748A1 (ja) * 2003-02-20 2004-09-02 Senju Pharmaceutical Co., Ltd. 水性懸濁液剤
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye

Also Published As

Publication number Publication date
KR20070004750A (ko) 2007-01-09
EP2127655A1 (en) 2009-12-02
AU2005229006B9 (en) 2011-05-19
ES2330762T3 (es) 2009-12-15
HK1102551A1 (en) 2007-11-30
ATE441419T1 (de) 2009-09-15
WO2005094836A2 (en) 2005-10-13
MXPA06010849A (es) 2007-03-08
JP2007530573A (ja) 2007-11-01
TW200602030A (en) 2006-01-16
DE602005016392D1 (de) 2009-10-15
US20050222110A1 (en) 2005-10-06
AU2005229006B2 (en) 2011-01-20
CN1964719B (zh) 2010-05-05
EP1744759A2 (en) 2007-01-24
CN1964719A (zh) 2007-05-16
EP1744759B1 (en) 2009-09-02
CA2560824A1 (en) 2005-10-13
WO2005094836A3 (en) 2006-01-26
AU2005229006A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
BRPI0509220A (pt) método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio
CA2690111A1 (en) Anthelmintic combination
WO2005046618A3 (en) Methods of treating eczema
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
NZ600000A (en) Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions
AR034619A1 (es) Formulaciones de olopatadine para administracion topica
NZ718955A (en) Compositions comprising povidone-iodine
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
EA200700074A1 (ru) Способ повышения скорости заживления повреждения ( варианты ), устройство доставки перекиси водорода и композиция для лечения повреждений у млекопитающих
WO2003088906A3 (en) Methods of simultaneously treating ocular rosacea and acne rosacea
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
WO2007070637A3 (en) Method of treating open wounds using hypochlorous acid
HK1205677A1 (en) Mesenchymal stem cells and uses therefor
EA200701017A1 (ru) Применение рибозы-цистеина для лечения гипоксии
WO2004073584A3 (en) Cystitis treatment with high dose chondroitin sulfate
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
WO2007103765A3 (en) Treatment with cyclosporin a
AR033207A1 (es) Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac
BRPI0513395A (pt) uso de um esteróide para aumentar a permeabilidade cutánea
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
WO2003051301A3 (en) USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
JO3448B1 (ar) استخدام أزيثروميسين لتصنيع دواء لمعالجة إلتهابات العين
RU2010132613A (ru) Способ лечения и повышения качества жизни больных хроническим панкреатитом

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]